

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. With the global EP market projected to reach \$7.4B in 2022 with a 10.4% growth rate, BioSig is commencing a targeted commercial release of its **PURE EP™ System** and **expecting to generate revenue in 2020**. The Company's first product is a computerized system designed to reveal the full range of cardiac signals and to provide physicians with signal clarity during procedures performed to address cardiac arrhythmias. The **PURE EP™ System** received FDA 510(k) clearance in August 2018. BioSig has successfully completed over 160 patient cases to date and is currently enrolling patients at the Texas Cardiac Arrhythmia Institute at St. David's Medical Center and Mayo Clinic's Florida campus. BioSig's subsidiary, ViralClear Pharmaceuticals, Inc. is developing a broad-spectrum anti-viral agent that may treat COVID-19 and is currently enrolling patients into a Phase II clinical trial for COVID-19 at ten key sites, including Mayo Clinic. Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices.

PURE EP™ System



Key Growth Drivers

- Advanced Technology** – The non-invasive **PURE EP System** is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. The PURE EP System aims to minimize noise and artifacts, and acquire high-fidelity cardiac signals. Improving cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly **improving accuracy and efficiency of the EP studies and ablation procedures**.
- Market Opportunity** – 2018 MD&D Report states the **global EP device** market is expected to exceed more than **US \$7.4 billion by 2022** and is growing at a compound annual growth rate (CAGR) of 10.4%. The Company also operates within the rapidly emerging field of **bioelectronic medicine**, estimated at **\$25.11 billion in 2020 with projected annual growth of 10.27%**.
- KOL Support** – **Successful clinical use of the PURE EP™ System was led by two globally recognized leaders: Dr. Andrea Natale** of Texas Cardiac Arrhythmia Institute (TCAI) and **Prof. John M. Miller** of Indiana University. The Company achieved proof of concept validation through UCLA, and has performed twenty-one pre-clinical studies at Mayo Clinic, MN under the leadership of **Samuel J. Asirvatham, M.D.**, **Mayo Clinic's Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory**.

Recent Highlights

- Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased **from 40 to 80** subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices
- Announced positive responses confirming **PURE EP signals are preferred to conventional sources of intracardiac signals** in a blinded, independent analysis.
- Announced installation of the **PURE EP™ System** at Massachusetts General Hospital
- Announced closing of **\$17.8 million** BioSig Technologies common stock offering in June 2020
- ViralClear Pharmaceuticals, Inc. subsidiary **acquires rights to develop** broad spectrum anti-viral to treat COVID-19, Commenced **Phase II clinical trial at Mayo Clinic** in June 2020
- Announced closing of **\$10.8 million** at ViralClear level in May 2020
- Announced closing of **\$10 million** public offering of BSGM common stock in February 2020
- Successfully completed **100 patient cases with its PURE EP™ System**
- Commenced **patient cases at Mayo Clinic**, the **second institution** enrolling patients **in the PURE EP™ System Clinical Trial**
- Announced that the US Patent & Trademark Office allowed a **fifth utility patent covering PURE EP™**
- Announced **partnership with Reified** on development of **artificial intelligence (AI)** solutions in healthcare
- Commenced first Clinical Trial for its **PURE EP™ System** at TCAI

Market Snapshot
NASDAQ: BSGM

Price (10/02/20)	\$4.93
Average Volume (30 day)	952,579
52-Wk. Range	\$2.36 - \$12.43
Float	21.9M
Shares Outstanding	29.8M
Market Cap	\$148.00M

BioSig Technologies, Inc.

54 Wilton Road, 2nd Floor
Westport, CT 06880
www.biosig.com
info@biosigtech.com

Contact:
Kenneth L. Londoner, CEO
Phone: (203) 409-5444 x119
klondoner@biosigtech.com

Investor Relations
Andrew Ballou
Phone: (203) 409-5444, x133
aballou@biosigtech.com

PURE EP™ System

Proprietary Hardware and Software with Advanced Signal Processing Capabilities:

- To **Improve Signal Clarity** Through Reduction of ‘Noise’ and Artifacts
- To **Minimize Need for Repeat Procedures**
- To **Preserve Important Clinical Information**
- To **Shorten Procedure Times**
- To **Increase Confidence** in Performing Complex Ablations
- **Customizable** user control interface for a better understanding of ECG and intracardiac signals

Projected Global EP Market—10.4% Growth reaching \$7.4B by 2024

- **Global Ablation Procedure Growth: 8.4%** growth rate, from 973,220 in 2017 to 1,455 projected million in 2022.
- **Complex Ablation Procedures:** 440,629 in 2017 to 830,390 in 2022; **13.5% projected growth rate**
- Estimated 3,425 EP rooms in US; 3,915 EP rooms OUS

Collaborating with Leading EPs from:



MASSACHUSETTS GENERAL HOSPITAL



Management and Past Experience

Kenneth L. Londoner, MBA, Founder, Chairman, Chief Executive Officer, Director

Endicott Management Partners; J & W Seligman & Co; Director: Alliqua

Steve Chaussy, CPA, Chief Financial Officer

Liberski Inc; Anna & Co; Penske Truck Leasing, Ford, Hogg & Cobbe

Natasha Drapeau, Executive Vice President

IG Group Plc, London, UK; Augeous Consulting, Geneva, Switzerland

Barry Keenan, Ph.D, MBA, PMP, VP, Engineering

Medtronic, Nexeon MedSystems, Alfred Mann Institute for Biomedical Engineering; Alfred Mann Foundation for Scientific Research

John Kowalski, VP, Sales

Biosense Webster (Johnson & Johnson)

Andrew Ballou, VP, Investor Relations

Janney Montgomery Scott LLC., RBC Capital Markets

Todd Wiltshire, Senior VP, Corporate Development

Fidelity Investments, Morgan Stanley

Julie Stephenson, VP, Clinical Affairs

Medtronic, Boston Scientific, Guidant Corporation

Olivier Chaudoir, Sr. Director of Marketing

Biosense Webster, DePuy Synthes

Proven Team

BioSig is operated by a **proven management team** and a **premier Board of Directors** with high levels of inside equity ownership.

BioSig brought together **leading physicians, executives and engineering experts** from leading medical centers of excellence, healthcare programs, Fortune 500 Companies and elite educational institutions for its **Advisory Board** including Mayo Clinic, Mount Sinai Medical Center, UCLA, Johnson & Johnson, Nasdaq and Prudential Securities.

Kenneth L. Londoner, Chairman & CEO, has a wealth of knowledge and experience that spans many decades and includes founding, running, and serving as Director to a number of life science companies. Mr. Londoner began his career with J. & W. Seligman & Co., Inc., a leading institutional money management firm where he rose from research analyst to managing \$3.5 billion in mutual funds, pension funds, and international assets.

Steve Chaussy, CFO has acted as a consultant for small publicly traded entities with a special emphasis towards SEC reporting and compliance; and served as CFO for a large private distribution and wholesaling company, where he gained international experience.

Directors

Donald E. Foley, Director - Former CEO & Chair: Wilmington Trust; Sr VP, Treas & Dir: ITT Corp; Asst Treas: International Paper Co.

David Weild IV, MBA, Director - Current Chairman & CEO; Weild & Co.; Former Vice Chairman: NASDAQ; Former Head of Corporate Finance & Equity Markets: Prudential Securities

Patrick J. Gallagher, MBA, Director - Mg Dir: Laidlaw & Co.; Kinex Pharmaceuticals; Director: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody

Jeffrey F. O'Donnell, Sr., Director - Former CEO, Director: Trice Medical; Current Chair: SpectraWave; Director: AdvaMed Accel; Founder: Embrella Cardiovascular (sold to Edwards Lifesciences); CEO: PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash; Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director: Cardiac Science, Endologix

Andrew Filler, Director - Current Partner & General Counsel: Sherpa Technology Group, Nanosys; IP Counsel: Previvo Genetics; Board: Aira Technologies. Former: Caliper Life Sciences (sold to Perkin Elmer), Weil, Gotshal & Manges

Jerome B. Zeldis, M.D., Ph.D, Director - Executive Chair and Acting Chief Medical Officer of ViralClear Pharmaceuticals, Inc.

Samuel E. Navarro, Director - Managing Partner: Gravitas Healthcare, LLC; Former Managing Director and Global Head of Medical Technology Investment Banking: Cowen & Company

Martha Pease, Director - Current Partner and Director at BCG (Boston Consulting Group)

Anthony Zook, Director - Former Vice President & Executive Officer at AstraZeneca Plc

Analyst Coverage: **Laidlaw & Co**

Investment Highlights

- Member of the **Russell 3000® Index**
- Conducting **First Clinical Trial with PURE EP™ System**
- Significant Insider Ownership
- **10-year Strategic Collaboration with Mayo Clinic**
- Core competency in Basic Science, Capital Markets and Capital Architecture
- **IP Strategy** Led by Sherpa Technology Group and Sterne Kessler Goldstein & Fox.—31 allowed/issued design and utility patents
- **FDA clearance** achieved
- Proven Management Team and Board of Directors
- **Global and Growing Addressable Market**
- Operates Within Rapidly Emerging Field of **Bioelectronic Medicine**
- **High-Growth Sector Earns Innovation Premium, Aggressive M&A**

Current Cardiac Arrhythmia Epidemic (1 In 18 or 14.4M Americans)

Two of the most prevalent, complex and potentially deadly types of arrhythmias today are **Atrial Fibrillation (AF)** and **Ventricular Tachycardia (VT)**. Ventricular arrhythmias account for approximately **300,000 sudden deaths per year** in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting **33.5 million people worldwide**, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately \$6B annually; adding other indirect costs brings **AF total cost to \$26B**.